Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 434

Similar articles for PubMed (Select 16413762)

1.

Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.

Verbeeck RK, Kanfer I, Walker RB.

Eur J Pharm Sci. 2006 May;28(1-2):1-6. Epub 2006 Jan 18. Review.

PMID:
16413762
2.

Status of generic substitution: problematic drug classes reviewed.

Ross MB.

Hosp Formul. 1989 Aug;24(8):441-4, 447-9.

PMID:
10294356
3.

[Generic drugs: quality, efficacy, safety and interchangeability].

Tschabitscher D, Platzer P, Baumgärtel C, Müllner M.

Wien Klin Wochenschr. 2008;120(3-4):63-9. doi: 10.1007/s00508-008-0927-3. German.

PMID:
18322766
4.

[Bioequivalence studies of pharmaceutical preparations].

Vetchý D, Frýbortová K, Rabisková M, Danecková H.

Cas Lek Cesk. 2007;146(5):431-3. Review. Czech.

PMID:
17554963
5.

What makes a generic medication generic?

Howland RH.

J Psychosoc Nurs Ment Health Serv. 2009 Dec;47(12):17-20. doi: 10.3928/02793695-20091103-99.

PMID:
20000278
6.
7.

Regulatory aspects of drug dissolution from a European perspective.

Graffner C.

Eur J Pharm Sci. 2006 Nov;29(3-4):288-93. Epub 2006 May 16. Review.

PMID:
16950606
8.

International harmonization of bioequivalence studies and issues shared in common.

Nakai K, Fujita M, Ogata H.

Yakugaku Zasshi. 2000 Nov;120(11):1193-200.

PMID:
11190204
9.

Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).

Raw AS, Furness MS, Gill DS, Adams RC, Holcombe FO Jr, Yu LX.

Adv Drug Deliv Rev. 2004 Feb 23;56(3):397-414. Review.

PMID:
14962589
10.

Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective.

Chen ML.

Adv Drug Deliv Rev. 2008 Mar 17;60(6):768-77. Epub 2007 Nov 12. Review.

PMID:
18077051
11.

Concerns about the safety of obesity agents from a manufacturing perspective.

Kanfer I.

Postgrad Med. 2008 Jul;120(2):42-5. doi: 10.3810/pgm.2008.07.1789. Review.

PMID:
18654067
12.

The debate over substitution policy. Its evolution and scientific basis.

Schwartz LL.

Am J Med. 1985 Aug 23;79(2B):38-44. Review.

PMID:
3898831
13.

Bioequivalence and generic prescribing: an industrial view.

Pidgen A.

J Pharm Pharmacol. 1996 Jan;48(1):11-6. Review.

PMID:
8722487
14.

A review of the safety of generic drugs.

Dighe SV.

Transplant Proc. 1999 May;31(3A Suppl):23S-24S. Review.

PMID:
10330955
15.

Critical therapeutic categories: a contraindication to generic substitution?

Colaizzi JL, Lowenthal DT.

Clin Ther. 1986;8(4):370-9.

PMID:
3731208
16.

Solid form screening--a review.

Aaltonen J, Allesø M, Mirza S, Koradia V, Gordon KC, Rantanen J.

Eur J Pharm Biopharm. 2009 Jan;71(1):23-37. doi: 10.1016/j.ejpb.2008.07.014. Epub 2008 Jul 31. Review.

PMID:
18715549
17.
18.

A survey of top 200 drugs--inconsistent practice of drug strength expression for drugs containing salt forms.

Prohotsky DL, Zhao F.

J Pharm Sci. 2012 Jan;101(1):1-6. doi: 10.1002/jps.22735. Epub 2011 Sep 8.

PMID:
21905029
19.

Solid-state analysis of the active pharmaceutical ingredient in drug products.

Newman AW, Byrn SR.

Drug Discov Today. 2003 Oct 1;8(19):898-905. Review.

PMID:
14554018
20.

[Bioavailability, proof of efficacy and their consequences for drug legislation (author's transl)].

Schnieders B.

Arzneimittelforschung. 1976;26(1A):158-63. German.

PMID:
947195
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk